A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Approximately 42 HIV-negative women, aged >18 and < 50, will be enrolled in this study. Each
volunteer will have a 2:1 chance of receiving Dapivirine Gel-002 versus placebo. The
volunteers will receive investigational product for a total of 42 days.